Related references
Note: Only part of the references are listed.Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation
Markus J. Harder et al.
BLOOD (2017)
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study
Michael Loschi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria
Zhuoer Lin et al.
BLOOD (2015)
Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria
Tolulase Olutogun et al.
BLOOD TRANSFUSION (2015)
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria
Antonio M. Risitano et al.
BLOOD (2014)
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria
Tommaso Rondelli et al.
HAEMATOLOGICA (2014)
Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria
David J. Araten et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Genetic Variants in C5 and Poor Response to Eculizumab
Jun-ichi Nishimura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of Eculizumab in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
Ulrike M. Reiss et al.
PEDIATRIC BLOOD & CANCER (2014)
Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab
Suresh K. Krishnan et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment
Antonio M. Risitano et al.
BLOOD (2012)
The tick-over theory revisited: Is C3 a contact-activated protein?
Bo Nilsson et al.
IMMUNOBIOLOGY (2012)
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival
Richard J. Kelly et al.
BLOOD (2011)
Management of Paroxysmal Nocturnal Haemoglobinuria: a personal view
Lucio Luzzatto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena
Alexander Roeth et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
Anovel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement
Margaret A. Lindorfer et al.
BLOOD (2010)
Paroxysmal nocturnal hemoglobinuria and eculizumab
Lucio Luzzatto et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization
Anita Hill et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Molecular basis of familial hemophagocytic lymphohistiocytosis
Valentina Cetica et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Paroxysmal Nocturnal Hemoglobinuria -- Hemolysis before and after Eculizumab.
Antonio M. Risitano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
Antonio M. Risitano et al.
BLOOD (2009)
Morphological definition of CD71 positive reticulocytes by various staining techniques and electron microscopy compared to reticulocytes detected by an automated hematology analyzer
Mari Kono et al.
CLINICA CHIMICA ACTA (2009)
Paroxysmal nocturnal hemoglobinuria:: natural history of disease subcategories
Regis Peffault de Latour et al.
BLOOD (2008)
Hemoglobin normalization after spienectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab
Antonio M. Risitano et al.
BLOOD (2008)
The spectrum of complement alternative pathway-mediated diseases
V. Michael Holers
IMMUNOLOGICAL REVIEWS (2008)
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
BLOOD (2007)
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Russell P. Rother et al.
NATURE BIOTECHNOLOGY (2007)
Factor H-mediated cell surface protection from complement is critical for the survival of PNH erythrocytes
Viviana P. Ferreira et al.
BLOOD (2007)
Primary chronic cold agglutinin disease: An update on pathogenesis, clinical features and therapy
Sigbjorn Berentsen et al.
HEMATOLOGY (2007)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Red blood cell age determines the impact of storage and leukocyte burden on cell adhesion molecules, glycophorin A and the release of annexin V
RL Sparrow et al.
TRANSFUSION AND APHERESIS SCIENCE (2006)
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
A Hill et al.
BLOOD (2005)
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
P Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Clinical manifestations of paroxysmal nocturnal hemoglobinuria: Present state and future problems
WF Rosse et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)
Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria
DS Holt et al.
BLOOD (2001)
Share Paper
